Turnstone Biologics Corp. (TSBX)
NASDAQ: TSBX · IEX Real-Time Price · USD
3.050
+0.180 (6.27%)
At close: May 10, 2024, 4:00 PM
3.120
+0.070 (2.30%)
After-hours: May 10, 2024, 7:47 PM EDT
Company Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors.
The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.
The company was founded in 2014 and is based in LA Jolla, California.
Turnstone Biologics Corp.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Dr. Sammy J. Farah M.B.A., Ph.D. |
Contact Details
Address: 9310 Athena Circle, Suite 300 La Jolla, California 92037 United States | |
| Phone | 347-897-5988 |
| Website | turnstonebio.com |
Stock Details
| Ticker Symbol | TSBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001764974 |
| CUSIP Number | 90042W100 |
| ISIN Number | US90042W1009 |
| Employer ID | 83-2909368 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer |
| Dr. Michael F. Burgess M.D., MBChB, Ph.D. | Interim Chief Medical Officer and Executive Director |
| Saryah Azmat | Chief Business Officer |
| Dr. Vijay Chiruvolu M.B.A., Ph.D. | Interim Chief Technology Officer |
| Dr. Stewart Abbot Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |